Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDIT3 | P35638 | 1/20 | 0.44 |
| ▸ | MMP13 | P45452 | 2/20 | 0.41 |
| ▸ | NAMPT | P43490 | 8/20 | 0.40 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.40 |
| ▸ | GCK | P35557 | 3/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.36 |
| ▸ | AKT1 | P31749 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | MMP8 | P22894 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1268648 | 0.82 | MMP13 (0.45) | DDIT3MMP13NAMPTTXNRD1MMP1 | |
| SCHEMBL2632976 | 0.81 | DDIT3 (0.44) | DDIT3NAMPTTXNRD1PIK3CAAKT1 | |
| SCHEMBL1938630 | 0.81 | DDIT3 (0.44) | DDIT3MMP13NAMPTTXNRD1 | |
| SCHEMBL5319901 | 0.81 | MMP13 (0.45) | DDIT3MMP13TXNRD1MMP1 | |
| SCHEMBL23633178 | 0.81 | MMP13 (0.44) | DDIT3MMP13NAMPTTXNRD1MMP1 | |
| SCHEMBL15231519 | 0.77 | CCR6 (0.46) | DDIT3MMP13NAMPTMMP1 | |
| SCHEMBL17374627 | 0.77 | MMP13 (0.63) | MMP13TXNRD1MMP1MMP8 | |
| SCHEMBL5321127 | 0.77 | DDIT3 (0.47) | DDIT3NAMPT | |
| SCHEMBL2632975 | 0.77 | DDIT3 (0.53) | DDIT3MMP13TXNRD1MMP1MMP8 | |
| SCHEMBL15573285 | 0.74 | CA2 (0.37) | MMP13MMP1MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7893077-B2 | Bisaryl-sulfonamides | AMGEN INC. (US) | 2011-02-22 | — | — | US | disclosed |
| EP-1786782-B1 | BISARYL-SULFONAMIDES | AMGEN INC (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20090221584-A1 | Bisaryl-sulfonamides | AMGEN INC. | 2009-09-03 | — | — | US | disclosed |
| US-7544702-B2 | Bisaryl-sulfonamides | AMGEN INC. (US) | 2009-06-09 | — | — | US | disclosed |
| EP-1786782-A2 | BISARYL-SULFONAMIDES | Amgen Inc. (US) | 2007-05-23 | — | — | EP | disclosed |
| US-20060084802-A1 | Bisaryl-sulfonamides | AMGEN INC. | 2006-04-20 | — | — | US | disclosed |
| WO-2006020830-A2 | BISARYL-SULFONAMIDES | AMGEN INC. (US) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221584-A1 | Bisaryl-sulfonamides | PPARD, PPARA, PPARG | DDIT3 2153/4885MMP13 1390/4885NAMPT 1256/4885 |
| US-20060084802-A1 | Bisaryl-sulfonamides | PPARD, PPARA, PPARG | DDIT3 2153/4885MMP13 1390/4885NAMPT 1256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.